BC
Boxer Capital Portfolio holdings
AUM
$2.04B
1-Year Return
108.35%
This Quarter Return
+24.79%
1 Year Return
+108.35%
3 Year Return
+260.95%
5 Year Return
+1,103.68%
10 Year Return
–
AUM
$1.9B
AUM Growth
+$119M
(+6.7%)
Cap. Flow
+$42.3M
Cap. Flow
% of AUM
2.23%
Top 10 Holdings %
Top 10 Hldgs %
50.01%
Holding
78
New
5
Increased
8
Reduced
9
Closed
7
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$30.9M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$20.2M |
| 3 |
Geron
GERN
|
$19.6M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$17.7M |
| 5 |
Viking Therapeutics
VKTX
|
$14.1M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$22.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$20.7M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$18.1M |
| 4 |
Veru
VERU
|
$11.4M |
| 5 |
Altimmune
ALT
|
$6.39M |
Sector Composition
| 1 | Healthcare | 99.67% |
| 2 | Financials | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
PMV Pharmaceuticals
PMVP
$76.3M
| $27.5M | 1.45% |
3,163,795
| – | – |
|
|
BLU
27
DELISTED
BELLUS Health Inc.
BLU
| $26.3M | 1.39% |
3,200,000
| – | – |
|
28
Day One Biopharmaceuticals
DAWN
$759M
| $25.6M | 1.35% |
1,189,943
| – | – |
|
29
Avidity Biosciences
RNA
$6.24B
| $24.9M | 1.31% |
1,121,327
| – | – |
|
30
Xenon Pharmaceuticals
XENE
$2.98B
| $23.7M | 1.25% |
600,000
| – | – |
|
|
31
Geron
GERN
$880M
| $19.6M | 1.03% |
+8,100,000
| New | +$19.6M |
|
32
Exelixis
EXEL
$10.1B
| $18.4M | 0.97% |
1,150,000
-100,000
| -8% | -$1.6M |
|
|
PNT
33
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $18.2M | 0.96% |
2,500,000
| – | – |
|
34
Prothena Corp
PRTA
$442M
| $18.1M | 0.95% |
300,000
| – | – |
|
35
89bio
ETNB
$1.28B
| $17.8M | 0.94% |
1,400,000
| – | – |
|
|
ISEE
36
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $17.7M | 0.93% |
+825,000
| New | +$17.7M |
|
|
RAIN
37
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $17.2M | 0.91% |
2,147,212
+972,212
| +83% | +$7.78M |
|
|
38
Viking Therapeutics
VKTX
$2.98B
| $14.1M | 0.74% |
+1,500,000
| New | +$14.1M |
|
39
Nurix Therapeutics
NRIX
$697M
| $13.4M | 0.71% |
1,224,892
| – | – |
|
40
Fate Therapeutics
FATE
$112M
| $12.6M | 0.66% |
1,250,000
+900,000
| +257% | +$9.08M |
|
41
Ascendis Pharma
ASND
$12B
| $11.6M | 0.61% |
95,000
+25,000
| +36% | +$3.05M |
|
42
Cullinan Oncology
CGEM
$408M
| $11.3M | 0.6% |
1,074,082
| – | – |
|
43
Iovance Biotherapeutics
IOVA
$796M
| $9.62M | 0.51% |
1,505,133
-430,000
| -22% | -$2.75M |
|
44
Oric Pharmaceuticals
ORIC
$1.05B
| $7.36M | 0.39% |
1,054,000
| – | – |
|
45
Gossamer Bio
GOSS
$571M
| $7.24M | 0.38% |
3,336,928
-235,000
| -7% | -$510K |
|
|
PANA
46
DELISTED
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
| $6.21M | 0.33% |
500,000
| – | – |
|
47
Cogent Biosciences
COGT
$1.81B
| $6.07M | 0.32% |
525,000
+100,000
| +24% | +$1.16M |
|
48
BioAtla
BCAB
$29.3M
| $5.66M | 0.3% |
686,347
| – | – |
|
49
Arvinas
ARVN
$559M
| $5.13M | 0.27% |
+150,000
| New | +$5.13M |
|
50
Cabaletta Bio
CABA
$141M
| $5M | 0.26% |
540,000
| – | – |
|